Amgen (AMGN) R&D In Process (2021)
Amgen's quarterly R&D In Process came in at $1.5 billion in Q2 2021.
Amgen has reported R&D In Process for 1 years, with the latest figure at $1.5 billion in Q2 2021.
- For the quarter ending Q2 2021, R&D In Process changed N/A year-over-year to $1.5 billion; the trailing twelve-month figure through Jun 2022 stood at $1.5 billion (changed 0.0% YoY), and the FY2021 full-year result was $1.5 billion, changed N/A from the prior year.
- R&D In Process for Q2 2021 stood at $1.5 billion.
- The five-year high for R&D In Process was $1.5 billion in Q2 2021, with the low at $1.5 billion in Q2 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D In Process (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | 11.30 Bn |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 584.00 Mn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | - |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 744.00 Mn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | - |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 107.00 Mn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 137.00 Mn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 94.00 Mn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 1.51 Bn |